Irinotecan Hcl-3-Water Koanaa

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hcl-3-Water Koanaa, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic colorectal cancer and other solid tumors as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Hcl-3-Water Koanaa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hydrochloride is used in oncology to target cancers that are treated with topoisomerase I inhibition. - Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens. - Advanced colorectal cancer: provides disease control as part of second‑line therapy. - Other solid tumors: used in combination protocols for gastric, pancreatic, and lung cancers where topoisomerase I inhibition is indicated.

Irinotecan Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea: may be managed with anti‑emetics. - Fatigue: general tiredness experienced during treatment. - Neutropenia: reduced white blood cell count increasing infection risk.

Serious or Rare Side Effects: - Severe neutropenic infection: life‑threatening bacterial infection. - Febrile neutropenia: fever with low neutrophil count. - Acute cholinergic syndrome: abdominal cramps, sweating, and bradycardia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks. - Monitor blood counts: regular CBC to detect neutropenia. - Assess liver function: dose adjustments may be needed for hepatic impairment. - Evaluate renal function: consider renal status before administration. - Use anti‑diarrheal prophylaxis: loperamide may reduce severity of diarrhea. - Avoid in patients with known hypersensitivity to irinotecan or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Hydrochloride interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia and diarrhea. - Concurrent use of other myelosuppressive agents: can exacerbate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): increased bleeding risk due to mucosal damage. - Anticholinergic drugs (e.g., atropine): may mask cholinergic syndrome symptoms. - Proton pump inhibitors: possible alteration of drug metabolism, monitor efficacy.